IOBTQ (IO Biotech) Inventories, Finished Goods: $0.00 Mil (As of Sep. 2025)


What is IO Biotech Inventories, Finished Goods?

IO Biotech IOBTQ +27.50% Inventories, Finished Goods is $0.00 Mil as of Sep. 2025. The stock has 1 warning sign investors should review.

IO Biotech Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for IO Biotech's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IO Biotech Inventories, Finished Goods Chart

IO Biotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

IO Biotech Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IO Biotech Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $0.00 Mil mean?
IO Biotech (IOBTQ) has a Inventories, Finished Goods of $0.00 Mil as of Sep. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on IO Biotech and its competitors.
Is IO Biotech's Inventories, Finished Goods too high?
IO Biotech's current Inventories, Finished Goods is $0.00 Mil.
How does IO Biotech's Inventories, Finished Goods compare to CNBX and ENDV?
IO Biotech's Inventories, Finished Goods of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on IO Biotech and its competitors. IO Biotech's current Inventories, Finished Goods is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IO Biotech stock overvalued right now?
IO Biotech (IOBTQ) has a current Inventories, Finished Goods of $0.00 Mil. The current Inventories, Finished Goods is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For IO Biotech (IOBTQ), the current Inventories, Finished Goods is $0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IO Biotech Business Description

Address Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.